Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.37 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29715836 | 1.00 | KDM4E (0.41) | KDM4ELMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL21647551 | 0.93 | KDM4E (0.38) | KDM4ELMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL26688486 | 0.89 | TUBB4A (0.41) | KDM4ELMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL21647631 | 0.89 | L3MBTL1 (0.45) | KDM4ELMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL21647516 | 0.85 | KMT2A (0.42) | KDM4ELMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL23441117 | 0.85 | ALDH1A1 (0.44) | KDM4ELMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL21647511 | 0.80 | PABPC1 (0.43) | KDM4ELMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL29715752 | 0.80 | KDM4E (0.41) | KDM4ELMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL23441105 | 0.80 | KDM4E (0.41) | KDM4ELMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL25229367 | 0.80 | KDM4E (0.42) | KDM4ELMNAALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114729004-B | Heterocyclic compounds | 日商泛美克斯股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-12202829-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-11639354-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2022-12-22 | — | — | US | disclosed |
| CN-114729004-A | Heterocyclic compounds | 日商泛美克斯股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4006037-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2022-06-01 | — | — | EP | disclosed |
| WO-2022002102-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2022-01-06 | — | — | WO | disclosed |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2021-06-17 | — | — | US | disclosed |
| EP-3831811-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2021-06-09 | — | — | EP | disclosed |
| CN-112533898-A | Heterocyclic compounds | 日商泛美克斯股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2020027225-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | KDM4E 2577/4885LMNA 1743/4885ALDH1A1 2510/4885 |
| US-11639354-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | KDM4E 2577/4885LMNA 1743/4885ALDH1A1 2510/4885 |
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | IRAK1, IRAK2, IRAK4 | KDM4E 1311/4885LMNA 2019/4885ALDH1A1 927/4885 |
| US-12202829-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | KDM4E 2577/4885LMNA 1743/4885ALDH1A1 2510/4885 |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | KDM4E 2577/4885LMNA 1743/4885ALDH1A1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.